Viral Envelope Modification via Exogenous Anchoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying retroviral vectors are inconvenient and time-consuming, requiring genetic modification of host cell lines, limiting the incorporation of proteins and polypeptides into viral envelopes, and making it difficult to introduce voluminous proteins or compounds into viral particles post-release from host cells.
Innovation Solution
The method of 'viral painting' involves exogenously adding compounds with GPI anchors to the lipid double layers of isolated viral particles, allowing for the anchoring of substances like proteins and cytokines into the viral envelope, altering its composition and characteristics without the need for genetic modification of virus-producing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If genetic modification of host cell lines is used to modify retroviral vectors, then viral envelope composition can be altered, but the process becomes inconvenient and time-consuming
Solution Approach 1:
The patent applies preliminary action by pre-modifying the viral envelope proteins in the supernatant before viral particle formation. By treating the supernatant with modifying agents (e.g., chemical crosslinkers, enzymatic modifiers) prior to viral assembly, the envelope proteins are pre-conditioned to incorporate desired modifications. This eliminates the need for time-consuming genetic modification of host cell lines, as the modifications are applied exogenously to the viral particles themselves after release from host cells.
Solution Approach 2:
The patent uses intermediary substances such as chemical crosslinking agents (e.g., glutaraldehyde, carbodiimides) or enzymatic modifiers as mediators to alter the viral envelope composition. These intermediary agents facilitate the modification of envelope proteins without requiring direct genetic manipulation of the host cell. The intermediaries bridge between the desired modification and the viral envelope, enabling flexible composition changes through simple incubation steps.
2Quantity of substance
If genetic modification of host cell lines is used, then proteins and polypeptides can be incorporated into viral envelopes, but voluminous proteins or compounds cannot be introduced post-release
Solution Approach 1:
The patent applies self-service by enabling the viral particles to undergo self-modification after release from host cells. The modifying agents are added to the supernatant containing released viral particles, and the viral envelopes spontaneously incorporate the desired proteins or compounds through natural envelope protein dynamics. This self-service mechanism allows incorporation of voluminous proteins that would be difficult to express in host cells, as the modification occurs exogenously without cellular machinery constraints.
3Productivity
If rapid and flexible modification is achieved, then therapeutic applications and vaccine efficacy are enhanced, but viral infectivity must be maintained
Solution Approach 1:
The patent applies local quality by targeting modifications specifically to the viral envelope region without affecting the internal viral components. By using modifying agents that selectively interact with envelope proteins (e.g., surface-accessible crosslinkers, envelope-specific enzymes), the modification is localized to the envelope layer. This localized approach allows rapid composition changes while preserving the integrity of the viral core and maintaining infectivity, as the essential viral machinery remains unmodified.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and flexible modification of viral envelopes, enhancing the stability, infectivity, and immunogenicity of viral particles, allowing for targeted therapeutic applications and improved vaccine efficacy, while maintaining viral infectivity and allowing for specific tagging and modification of viral envelopes.
Implementation Method 1
the lipophilic membrane anchor domain becomes integrated into the lipid double layer of the virus envelope
Data Source
AI summary
Disclosed are methods of treatment of a subject, such as a method of vaccination, immunomodulation or gene therapy of a subject. These methods comprise administering to the subject a modified enveloped viral particle, wherein the modified enveloped viral particle has been obtained by a method comprising the steps of a) incubating a fluid containing enveloped viral particles with one or more reactants consisting of a hydrophilic target domain and a lipophilic membrane anchor domain, wherein the lipophilic membrane anchor domain becomes integrated into the lipid double layer of the envelope of the viral particle, wherein the hydrophilic target domain becomes exposed to the fluid; and b) separating enveloped modified viral particles from excessive reactants.